跳至主要内容
临床试验/NCT01391715
NCT01391715撤回3 期

Double-dose Rabeprazole Accelerates and Sustains the Control of Symptoms in Patients With NERD: a Randomized Controlled Trial

Inje University1 个研究点 分布在 1 个国家开始时间: 2011年8月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
撤回
试验地点
1
主要终点
symptom improvement at 2 week after double dose rabeprazole treatment

研究概览

简要总结

To the best of our knowledge, there has been no randomized controlled trial to compare double dose PPI therapy with standard one dose PPI therapy for NERD patients. Thus, we hypothesize that a double dose PPI would accelerate and sustain the control of symptom in NERD patients.

详细描述

In Asian, the majority of GERD cases are cases of nonerosive reflux esophagitis(NERD). NERD is a difficult -to-treat acid reflux condition even with PPI compared to reflux esophagitis(RE). In addition, the quality of life of NERD patients is quite low, NERD patients need quicker and more effective treatment options. At present, PPI-based step-down treatment is recommended for GERD patients. Doubling th PPI dose has become a commonly practiced therapeutic strategy in patients with GERD who failed PPI once daily. In patients with symptomatic GERD who failed the one dose PPI can increase the rate of overall symptom improvement by 22-26%. There are various mechanisms for standard dose PPI failure in GERD patients. Esophageal hypersensitivity is likely the underlying mechanism in a significant number of patients. Patients with the sensitive esophagus (normal endoscopy and pH test but positive symptom index) were more likely to respond to PPI twice a day. It is thus of clinical interest to determine whether an increased dosage of PPI can achieve rapidly the control of symptoms for patient with NERD patients.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • heartburn and/or reflux at least twice weekly in the absence of visible esophageal mucosal breaks at endoscopy

排除标准

  • pregnancy
  • lactation
  • Hx of gastric surgery
  • Hx of gastric cancer or peptic ulcer
  • major medical problems (including CHF, renal failure, COPD, asthma, liver cirrhosis)
  • severe systemic illness
  • Hx of malignancy, allergy Hx to rabeprazole
  • patients who had taken antibiotics
  • antisecretory agents including H2-blocker
  • PPI within 4 weeks before endoscopy
  • current usage of steroids, NSAIDs, aspirin, anticoagulant medication

研究组 & 干预措施

Double dose rabeprazole

Active Comparator

Rabeprazole 20m bid per day will be given for 2 weeks

干预措施: rabeprazole (Drug)

standard dose rabeprazole

Placebo Comparator

rabeprazole 20mg per day will bi given for 2 weeks

干预措施: standard dose rabeprazole (Drug)

结局指标

主要结局

symptom improvement at 2 week after double dose rabeprazole treatment

时间窗: Two weeks

symptom improvement according to FSSG(the frequency scale for the symptoms of GERD) at 2 week after double dose rabeprazole treatment

次要结局

  • sustained symptom improvement at 6 week after treatment(6 weeks)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Eun Hee Seo

Fellow

Inje University

研究点 (1)

Loading locations...

相似试验